Meeting
2018 ASCO Annual Meeting
Comprehensive genomic profiling of brain tumors to provide targeted therapy options and diagnostic certainty for oligodendrogliomas.
Authors
Lee A. Albacker
Foundation Medicine, Cambridge, MA
Lee A. Albacker , Dean Pavlick , Jeffrey S. Ross , Glenn Jay Lesser , Robert John Corona , Howard Colman , Morris D. Groves , Sigmund H. Hsu , Andrew S. Chi , Vincent A. Miller , Garrett Michael Frampton , Shakti Ramkissoon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2039)
DOI
10.1200/JCO.2018.36.15_suppl.2039
Abstract #
2039
Poster Bd #
197
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay
First Author: Antonio Marcilio Padula Omuro
Poster
2023 ASCO Annual Meeting
New ESMO scale for clinical actionability of molecular targets (ESCAT) for gliomas based on a multicentric real world data cohort using next-generation sequencing (NGS).
First Author: Oriol Mirallas
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2019 ASCO Annual Meeting
Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.
First Author: Ian M. Silverman